Advertisement
MONCYTE Health joins EUR 7 million project

MONCYTE Health has been selected to join a 4-year Horizon funded project as a core industrial partner.
In this project MONCYTE Health is part of a consortium of 15 internationally leading institutions, working together to enable new strategies for earlier diagnosis and co-management of familial hypercholesterolemia (FH).
This can help clinicians select more effective personalized treatments for patients with high cholesterol.
MONCYTE Health was selected, as part of this EUR 7.2 million project, as its technology provides novel insight into the biological processes underlying FH. This can help clinicians select more effective personalized treatments for patients with high cholesterol. Moreover, together with multiomics and AI tools, MONCYTE Health’s technology will assist in the identification of novel pathways and cellular mechanisms contributing to disease progression. This is important as genetic testing confirms the disorder in only around half of FH cases, with the cause of the rest being unknown, preventing the best clinical management of patients.
The FH-EARLY research project
The FH-EARLY research project aims to make a difference in healthcare interventions in areas of high public health need, facilitated by well-defined data flows, identifying new mechanisms through multiomics, explainable AI modeling and co-creation with families with FH and caregivers. The project will develop three interrelated solutions for FH: an array for earlier diagnosis, an assay for risk stratification, and co-management strategies.
“People with FH present a high cardiovascular risk, but these individuals are often not being clinically identified. Our technology provides valuable insights on how cholesterol is transported and processed in human cells, and since the most important cholesterol-lowering treatments function at the cellular level, this type of technology is essential to disease understanding and identifying opportunities for providing earlier diagnosis, and risk stratification for FH, and other cardiovascular diseases,” says Tamara Alagirova, CEO & co-founder at MONCYTE Health.
Published: January 14, 2025
Advertisement